WuXi Biologics (Cayman) Inc.

    Jurisdiction
    China
    LEI
    5493001TD2TH6VDTJU11
    ISIN
    US98260N1081 (WXXWY)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    51 / 100
    Even with peer group:
    51 / 100
    Fair value (Benjamin Graham formula)
    €7.68 20.5% overvalued
    Fundamental strength relative to industry (Mohanram G-Value)
    6 / 7

    Profile

    WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. Read full profile

    Fundamentals

    Net revenue
    €4.25B
    Gross margin
    40.5%
    EBIT
    €1.06B
    EBIT margin
    25.0%
    Net income
    €803.82M
    Net margin
    18.9%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €2.56B -39.7% €536.80M -33.2%
    €2.97B +15.8% €613.29M +14.2%
    €3.42B +15.2% €721.69M +17.7%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Earnings Calls

    Add to watchlist

    Notifications